EirGenix Market Cap ($632.48 Million)
Market Cap & Net Worth: EirGenix (6589)
EirGenix market cap. EirGenix (TWO:6589) has a market capitalization of $632.48 Million (NT$20.08 Billion) as of November 1, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #10680 globally and #387 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying EirGenix's stock price NT$66.40 by its total outstanding shares 302337984 (302.34 Million). Also see 6589 cash generation efficiency for how efficiently the company converts equity into cash flow.
EirGenix Market Cap History (2016–2025)
EirGenix market cap history from 2016 to 2025. Data shows growth from $336.33 Million to $632.48 Million (5.61% CAGR). Check 6589 live share price for real-time trading data and today's change.
EirGenix Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how EirGenix's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 6589 net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.68x
EirGenix's market cap is 0.68 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $222.26 Million | $297.87 Million | -$174.85 Million | 0.75x | N/A |
| 2018 | $273.81 Million | $282.21 Million | -$367.79 Million | 0.97x | N/A |
| 2019 | $242.45 Million | $476.08 Million | -$860.92 Million | 0.51x | N/A |
| 2020 | $426.06 Million | $1.07 Billion | -$1.04 Billion | 0.40x | N/A |
| 2021 | $1.06 Billion | $1.70 Billion | -$42.58 Million | 0.63x | N/A |
| 2022 | $1.17 Billion | $1.48 Billion | -$115.54 Million | 0.79x | N/A |
| 2023 | $957.29 Million | $1.02 Billion | -$915.21 Million | 0.94x | N/A |
| 2024 | $685.82 Million | $1.01 Billion | -$698.34 Million | 0.68x | N/A |
Competitor Companies of 6589 by Market Capitalization
Companies near EirGenix in the global market cap rankings as of November 1, 2026. Also see 6589 current and non-current assets for a full breakdown of the balance sheet.
Key companies related to EirGenix by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of EirGenix (2016–2025)
Market capitalization of EirGenix from 2016 to today. Between 2016 and today, EirGenix's market cap moved from $336.33 Million to $ 632.48 Million, with a yearly change of 5.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | NT$632.48 Million | -7.78% |
| 2024 | NT$685.82 Million | -28.36% |
| 2023 | NT$957.29 Million | -18.29% |
| 2022 | NT$1.17 Billion | +10.31% |
| 2021 | NT$1.06 Billion | +149.28% |
| 2020 | NT$426.06 Million | +75.73% |
| 2019 | NT$242.45 Million | -11.45% |
| 2018 | NT$273.81 Million | +23.19% |
| 2017 | NT$222.26 Million | -33.92% |
| 2016 | NT$336.33 Million | -- |
End of Day Market Cap According to Different Sources
On Jul 17th, 2026 the market cap of EirGenix was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $632.48 Million USD |
| MoneyControl | $632.48 Million USD |
| MarketWatch | $632.48 Million USD |
| marketcap.company | $632.48 Million USD |
| Reuters | $632.48 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About EirGenix
EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatme… Read more